Search
AI-Powered Drug Development Stocks Soar in US After FDA Abandons Animal Testing Principles
2025-04-11 /
Read about 0 minute
Author：小编
After the market closed, stocks related to AI-powered drug development in the US market surged collectively, with notable gains across the board. Certara saw an increase of over 25%, Schrödinger rose 18%, Recursion Pharmaceuticals jumped 21%, Absci Corp advanced 17%, and Charles River gained 6%. This significant uptick was sparked by the recent announcement from the Food and Drug Administration (FDA), which revealed its plans to phase out animal testing for monoclonal antibodies and other drugs in favor of more effective human-relevant research methods. This transition heralds a promising future for the broader application of AI in the realm of drug development.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
